29 results
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
. Less frequent related SAEs reported in one patient each have included kidney injury, hepatic failure, bleeding, immune-mediated encephalitis, myositis … of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for Apexigen’s products, injury
S-4/A
9fzvso24jzq79g3o4s0
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
zlek wcvqw3q7n13l3r
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
10-K
kjg1q 4bfl0x2
29 Mar 22
Annual report
7:36am
10-Q
99x3z 14w28lihbw5
15 Nov 21
Quarterly report
7:54am
424B4
wc825
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1/A
EX-10.15
qxn 29jqypviev
30 Sep 21
IPO registration (amended)
9:11pm
S-1/A
EX-10.14
mlr8xu 85d
30 Sep 21
IPO registration (amended)
9:11pm
S-1
r3txye0hv qh
17 Sep 21
IPO registration
5:00pm